Cortes-Torres Edgar Joaquin, Hernandez-Gonzalez Heli, Morfin-Meza Kathia Dayana, Garcia Andrea, Monteon-Aspeitia Xochitl, Hernandez-Ramirez Vianney Teresita, Capetillo-Texson Carlos Enrique, Gomez-Sierra Jose Pablo, Villasenor-Rodriguez Alejandro Ruben, Gonzalez-Munoz Samantha Emily, Vazquez-Sanchez Sergio Jiram, Gonzalez-Ojeda Alejandro, Fuentes-Orozco Clotilde
Instituto Mexicano del Seguro Social (IMSS), Unidad Medica de Alta Especialidad (UMAE), Departamento de Cirugia General, Centro Medico Nacional de Occidente, Guadalajara, Jalisco, Mexico.
Instituto Mexicano del Seguro Social (IMSS), Unidad Medica de Alta Especialidad (UMAE), Unidad de Investigacion Biomedica 02, Centro Medico Nacional de Occidente, Guadalajara, Jalisco, Mexico.
Gastroenterology Res. 2025 Jun 16;18(4):175-181. doi: 10.14740/gr2032. eCollection 2025 Aug.
Colon cancer is a leading neoplasm worldwide, with 35% to 45% of colorectal cancer (CRC) patients exhibiting mutations in the Kirsten rat sarcoma oncogene (). This mutation affects disease development and serves as a biomarker for early detection, prognosis, and treatment. The objective of the present study was to identify the clinicopathological characteristics of colon cancer patients with mutations.
An analytical cross-sectional study involving patients with CRC was conducted. The study variables included sex, age, tumor location, and B-Raf proto-oncogene () mutations, and the presence of metastases.
The study involved 51 patients, with a mean (standard deviation) age of 61.4 ± 11.0 years. The most common tumor location was the sigmoid colon (35.3%), and 45.1% of patients were classified as tumor, node, metastasis (TNM) stage III with lymph node dissemination. Genetic analysis revealed that 35% of patients had mutations, while 32% had mutations. Notably, 61.1% of KRAS-positive patients also had mutations compared to 15.1% of KRAS-negative patients (P = 0.02).
KRAS-positive patients predominantly had tumors in the sigmoid colon. The coexistence of and mutations suggests a potential molecular interaction influencing disease progression. These findings highlight a distinct genomic pattern and the need for further research into its clinical implications.
结肠癌是全球主要的肿瘤，35%至45%的结直肠癌（CRC）患者在 Kirsten 大鼠肉瘤癌基因（）中存在突变。这种突变影响疾病发展，并作为早期检测、预后和治疗的生物标志物。本研究的目的是确定具有 突变的结肠癌患者的临床病理特征。
对CRC患者进行了一项分析性横断面研究。研究变量包括性别、年龄、肿瘤位置、 和B-Raf原癌基因（）突变以及转移情况。
该研究纳入了51例患者，平均（标准差）年龄为61.4±11.0岁。最常见的肿瘤位置是乙状结肠（35.3%），45.1%的患者被归类为伴有淋巴结扩散的肿瘤、淋巴结、转移（TNM）III期。基因分析显示，35%的患者有 突变，32%的患者有 突变。值得注意的是，KRAS阳性患者中有61.1%也有 突变，而KRAS阴性患者中这一比例为15.1%（P = 0.02）。
KRAS阳性患者的肿瘤主要位于乙状结肠。 和 突变的共存表明存在潜在的分子相互作用影响疾病进展。这些发现突出了一种独特的基因组模式以及对其临床意义进行进一步研究的必要性。
